Treatment of Depression in Children and Adolescents: A Systematic Review
Project Summary Title and Description
- Title
- Treatment of Depression in Children and Adolescents: A Systematic Review
- Description
- The purpose of the review is to examine the efficacy and comparative effectiveness of both benefits and harms of commonly used types of nonpharmacological and pharmacological treatments of child and adolescent depressive disorders.
- Attribution
- N/A
- Authors of Report
- N/A
- Methodology description
- We conducted a systematic review to evaluate the efficacy, comparative effectiveness, and moderators of benefits and harms of available nonpharmacological and pharmacological treatments for children and adolescent a confirmed diagnosis of a depressive disorder (DD)—major depressive disorder (MDD), persistent depressive disorder (PDD, previously termed dysthymia) or DD not otherwise specified (DD NOS). We searched five databases and other sources for evidence available from inception to May 29, 2019, dually screened the results, and analyzed eligible studies.
- PROSPERO
- CRD42018112150
- DOI
- https://doi.org/10.23970/AHRQEPCCER224
- Notes
- Data for this project were entered retrospectively by uploading data from Word. Titles of each evidence table are listed in the Appendix. https://pubmed.ncbi.nlm.nih.gov/32298061/
- Funding Source
- AHRQ
Key Questions
- 1. KQ 1a. In adolescents and children, what are the benefits and harms of nonpharmacological interventions for DDs (MDD, PDD/dysthymic disorders, or DD NOS)?
- 2. KQ 1b. How do these benefits and harms vary by subpopulation (e.g., patient characteristics, parent/caregiver characteristics, disorder characteristics, history of previous treatment, comorbid condition, exposure to a traumatic life event)?
- 3. KQ 2a. In adolescents and children, what are the benefits and harms of pharmacological interventions for DDs (MDD, PDD/dysthymic disorders, or DD NOS)?
- 4. KQ 2b. How do the benefits and harms vary by subpopulation (e.g., patient characteristics, disorder characteristics, history of previous treatment, comorbid condition, exposure to a traumatic life event)?
- 5. KQ 3a. In adolescents and children, what are the benefits and harms of combination interventions for DDs (MDD, PDD/dysthymic disorders, or DD NOS)?
- 6. KQ 3b. How do the benefits and harms vary by subpopulation (e.g., patient characteristics, disorder characteristics, history of previous treatment, comorbid condition, exposure to a traumatic life event)?
- 7. KQ 4a. In adolescents and children, what are the benefits and harms of collaborative care interventions for DDs (MDD, PDD/dysthymic disorders, or DD NOS)?
- 8. KQ 4b. How do the benefits and harms vary by subpopulation (e.g., patient characteristics, disorder characteristics, history of previous treatment, comorbid condition, exposure to a traumatic life event)?
- 9. KQ 5a. In adolescents and children, what are the comparative benefits and harms of treatments (pharmacological, nonpharmacological, combined, collaborative care interventions) for DDs (MDD, or PDD/dysthymic disorders, or DD NOS)?
- 10. KQ 5b. How do these benefits and harms vary by subpopulation (e.g., patient characteristics, disorder characteristics, history of previous treatment, comorbid condition, exposure to a traumatic life event)?
Associated Extraction Forms
Type |
---|
Standard |
Associated Studies (each link opens a new tab)
Downloadable Data Content
- Files
- XLSX Project Data